INDICATIONS FOR USE
CITRASATE DRY Acid Concentrate is indicated for use in patients undergoing extracorporeal bicarbonate hemodialysis for acute and chronic renal failure. CITRASATE DRY Acid Concentrate is intended to be used as one component in the preparation of dialysate in a three-stream proportioning hemodialysis machine according to a physician’s prescription.

REQUIREMENTS
For use only with a three-stream hemodialysis machine calibrated to proportion 1 part acid to 1.72 parts bicarbonate concentrate to 42.28 parts purified water that meets ISO 13959 or AAMI RD62 water quality requirements. Use only with 45X bicarbonate ('B') concentrates.

WARNING
• Failure to follow these Instructions for Use may result in patient injury or death.
• Check conductivity and pH of final dialysate prior to dialysis treatment and each time new concentrate is supplied to the machine. Use of a dialysate with incorrect conductivity or pH can cause serious injury or death. Refer to hemodialysis machine manufacturer’s instructions to determine conductivity and pH of final dialysate.
• This product contains citric acid and sodium acetate and yields 2.4 mEq/L of citrate and 0.3 mEq/L of acetate in the final dialysate. Following diffusion from the dialysate across the dialysis membrane to the blood, citrate and acetate are metabolized to bicarbonate. While the acetate from the acid concentrate will contribute to the serum bicarbonate level, the serum bicarbonate level of the patient during and immediately after the dialysis treatment is principally determined by the prescribed bicarbonate concentration which is set on the hemodialysis machine. Prescription of insufficient bicarbonate may contribute to metabolic acidosis; excessive bicarbonate may contribute to metabolic alkalosis. Both conditions are associated with poor patient outcomes.

CAUTION
• Federal law (U.S.A.) restricts this device to sale by or on the order of a physician.
• Wear safety glasses, gloves and clothing suitable to prevent exposure when handling. Acid concentrate can irritate eyes and skin.
• Do not use if any bag is open or damaged. Do not use unless all 4 bags are present.

Nominal Chemical Composition of CITRASATE DRY Case
16.44 kg NaCl, 0.419 kg KCl, 0.286 kg MgCl₂·6H₂O, 0.517 kg CaCl₂·2H₂O, 0.115 kg Na₂O≥H₂O, 0.432 kg Citric Acid, 3.09 kg Dextrose·H₂O, (Net Wt. 21.30 kg)

DIRECTIONS FOR MIXING
CITRASATE DRY must be mixed in Fresenius Dissolution Units with ISO 13959 or AAMI RD62 quality water. Add six cases of CITRASATE DRY to a 99 gallon Dissolution Unit or eight cases to a 132 gallon Dissolution Unit. Use entire contents of each bag (4) in this case. One case of CITRASATE DRY produces 62.5 liters (16.5 gallons) of liquid concentrate. Refer to the Dissolution Unit Operator’s Manual for detailed mixing instructions.

NOTE: CITRASATE DRY Acid Concentrate may compact or clump during handling and storage. Break clumps prior to mixing. Compacting or clumping does not affect chemical composition.

STORAGE AND DISPOSAL:
Store in a dry location between 5°C and 30°C (41°F and 86°F). Product can withstand an exposure to temperatures down to 0°C and up to 40°C (32°F to 104°F) for a period of up to 72 hrs. Dispose of unused concentrate in accordance with local, state and federal regulations.

Patents apply, visit www.fmcsa.com/patents

Exp. Date: 0FD2251-DA

LOT

FRESENIUS MEDICAL CARE
RENAL THERAPIES GROUP

Manufacturer: Fresenius Medical Care
Renal Therapies Group, LLC
Waltham, MA 02451 U.S.A.
1-800-323-5188

Printed in USA 71-4384.07 10/18